DETOUR1 Clinical Trial Study: 24-Month Data Presented at VIVA
DETOUR1 Clinical Trial includes a 79% primary patency, with 82% of patients maintaining freedom from major adverse events at 2 years post-procedure.
Clinical trials, studies, data, and updates reported in Medical Device News Magazine.
- Go to the previous page
- 1
- …
- 540
- 541
- 542
- 543
- 544
- 545
- 546
- …
- 584
- Go to the next page